Posted by Michael Wonder on 07 Sep 2022
AmMax Bio announces AMB-05X granted FDA fast track designation for the treatment of tenosynovial giant cell tumour
7 September 2022 - Proof of concept established in Phase 2 Trial of TGCT, with positive efficacy results across multiple clinical endpoints and favourable safety profile after 12 weeks of therapy with AMB-05X.
AmMax Bio today announced that the US FDA has granted AMB-05X fast track designation for the treatment of tenosynovial giant cell tumour.
